Harrow (HROW) Long-Term Deferred Tax (2019 - 2022)

Harrow (HROW) posted quarterly Long-Term Deferred Tax of $2.0 million for Q4 2022, down 87.69% quarter-over-quarter from $15.8 million in Q4 2020.

Harrow (HROW) Long-Term Deferred Tax (2019 - 2022) Analysis & Trends

Harrow's Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $2.0 million for Q4 2022.

In Q4 2022, Long-Term Deferred Tax changed N/A year-over-year to $2.0 million; the TTM figure through Dec 2022 stood at $2.0 million (changed N/A YoY), while the FY2022 annual figure was $2.0 million, changed N/A from the prior year.
Long-Term Deferred Tax for Q4 2022 stood at $2.0 million, down from $15.8 million in the prior quarter.
The five-year high for Long-Term Deferred Tax was $19.8 million in Q4 2019, with the low at $2.0 million in Q4 2022.
The 3-year median for Long-Term Deferred Tax is $15.8 million (2020), against an average of $12.5 million.
Peak annual rise in Long-Term Deferred Tax reached 20.13% in 2020, while the deepest fall reached 20.13% in 2020.
Harrow's Long-Term Deferred Tax stood at $19.8 million in 2019, then slipped by 20.13% to $15.8 million in 2020, then plunged by 87.69% to $2.0 million in 2022.
Business Quant data shows HROW's Long-Term Deferred Tax at $2.0 million in Q4 2022, $15.8 million in Q4 2020, and $19.8 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-
2	Teva Pharmaceutical Industries	43.08 Bn	39.43 Bn	2.15 Bn
3	Zoetis	31.54 Bn	29.87 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn
5	United Therapeutics	22.12 Bn	19.46 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-
10	Harrow	1.55 Bn	1.47 Bn	50.36 Mn

Download Data